GESSEL advises Polski Bank Komórek Macierzystych on an investment in Turkey
GESSEL advised Polski Bank Komórek Macierzystych S.A. (PBKM) on its purchase of a 70% stake in Famicord-Acibadem, newly created by carving out a part of the operations of Acıbadem Healthcare Group entrusted with collection, processing, analysis, and storage of umbilical blood.
Drawing on the familiarity with PBKM’s business built up over the course of our long-standing cooperation, we were able to fashion a tailor-made package comprising preparation of the transaction documentation and advice on the successive stages of implementation and closing. On GESSEL’s part, the project leader was Maciej Kożuchowski, heading up a team which included Piotr Rysiak, senior associate.
Polski Bank Komórek Macierzystych is the largest stem cell bank in Poland and leader of the international FamiCord Group managing stem cell banks located in Europe and Turkey. The main area of activity of PBKM is the acquisition, processing and long-term storage of stem cells extracted from umbilical cord blood and other post-natal tissues at the request of parents (family banking).
Acıbadem Health Group, established in 1991, is a leader in Turkey’s private health care market. It operates 21 hospitals and 13 clinics in four countries with an aggregate workforce of 22,500, including 4,000 physicians and 4,200 nurses. As of 2003, the Group’s operations include a stem cell bank, Acıbadem Labcell Umbilical Cord Blood Bank; most of the samples safeguarded by it are collected at own entities of the Acıbadem Hospitals Group.